Skip to main content
. 2013 Jan 2;304(5):F614–F622. doi: 10.1152/ajprenal.00285.2012

Fig. 1.

Fig. 1.

Outline of the two protocols. A: protocol used for determining the dose-response curve for the angiotensin II (ANG II) AT1 receptor antagonist candesartan, or the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), or the combination of the two. B: protocol used for investigating the roles of AT1 and A1 receptors on the regulation of intrarenal hemodynamics and tubular Na+ handling. STZ, streptozotocin.